Alaa Quisi1, Gökhan Alıcı2, Hazar Harbalıoğlu3, Ömer Genç4, Fahri Er4, Samir Allahverdiyev5, Abdullah Yıldırım6, Ibrahim Halil Kurt6. 1. Department of Cardiology, Medline Hospital Adana, Adana, Turkey. 2. Department of Cardiology, Okmeydanı Training and Research Hospital, İstanbul, Turkey. 3. Department of Cardiology, Düzce Atatürk State Hospital, Düzce, Turkey. 4. Department of Cardiology, Ağrı State Hospital, Ağrı, Turkey. 5. Department of Cardiology, İstanbul Aydın University VM Medical Park Florya Hospital, İstanbul, Turkey. 6. Department of Cardiology, Adana City Training and Research Hospital, Adana, Turkey.
Abstract
OBJECTIVE: Coronavirus disease 2019 (COVID-19) is an infectious disease that was first reported in December 2019 in Wuhan, China, and has since spread rapidly around the world, resulting in the ongoing COVID-19 pandemic. The CHA2DS2-VASc score is a well-validated risk stratification tool for predicting stroke in atrial fibrillation (AFib), as well as morbidity and mortality in several entities. The aim of this study was to evaluate the relationship between the CHA2DS2-VASc score and in-hospital mortality in patients with COVID-19, regardless of AFib. METHODS: This multicenter, retrospective study included a total of 349 patients with COVID-19 who were hospitalized between March 15 and April 15, 2020. The CHA2DS2-VASc score of each patient was calculated. Mortality outcomes were followed up until April 25, 2020. RESULTS: The CHA2DS2-VASc score was significantly higher in non-survivor COVID-19 patients than in survivor COVID-19 patients (p<0.001). Forward stepwise logistic regression analysis demonstrated that a CHA2DS2-VASc score of ≥3 (odds ratio [OR]: 12.613, 95% confidence interval [CI]: 3.092-51.451; p<0.001), and the leukocyte count (OR: 1.327, 95% CI: 1.145-1.538; p<0.001), C-reactive protein level (OR: 1.010, 95% CI: 1.002-1.018; p=0.012), and ferritin level (OR: 1.005, 95% CI: 1.003-1.007; p<0.001) on admission were independent predictors of in-hospital mortality of COVID-19 patients. CONCLUSION: The CHA2DS2-VASc score predicted in-hospital mortality in patients with COVID-19, regardless of AFib.
OBJECTIVE:Coronavirus disease 2019 (COVID-19) is an infectious disease that was first reported in December 2019 in Wuhan, China, and has since spread rapidly around the world, resulting in the ongoing COVID-19 pandemic. The CHA2DS2-VASc score is a well-validated risk stratification tool for predicting stroke in atrial fibrillation (AFib), as well as morbidity and mortality in several entities. The aim of this study was to evaluate the relationship between the CHA2DS2-VASc score and in-hospital mortality in patients with COVID-19, regardless of AFib. METHODS: This multicenter, retrospective study included a total of 349 patients with COVID-19 who were hospitalized between March 15 and April 15, 2020. The CHA2DS2-VASc score of each patient was calculated. Mortality outcomes were followed up until April 25, 2020. RESULTS: The CHA2DS2-VASc score was significantly higher in non-survivor COVID-19patients than in survivor COVID-19patients (p<0.001). Forward stepwise logistic regression analysis demonstrated that a CHA2DS2-VASc score of ≥3 (odds ratio [OR]: 12.613, 95% confidence interval [CI]: 3.092-51.451; p<0.001), and the leukocyte count (OR: 1.327, 95% CI: 1.145-1.538; p<0.001), C-reactive protein level (OR: 1.010, 95% CI: 1.002-1.018; p=0.012), and ferritin level (OR: 1.005, 95% CI: 1.003-1.007; p<0.001) on admission were independent predictors of in-hospital mortality of COVID-19patients. CONCLUSION: The CHA2DS2-VASc score predicted in-hospital mortality in patients with COVID-19, regardless of AFib.
Authors: Milena S Marcolino; Patricia K Ziegelmann; Maira V R Souza-Silva; I J B Nascimento; Luana M Oliveira; Luanna S Monteiro; Thaís L S Sales; Karen B Ruschel; Karina P M P Martins; Ana Paula B S Etges; Israel Molina; Carisi A Polanczyk Journal: Int J Infect Dis Date: 2021-01-12 Impact factor: 3.623